US-based Vernova's subsidiary, Macfarlan Smith, has completed a $10 million expansion of its mid-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Edinburgh, UK facility.

The expansion allows the company to handle highly active APIs and intermediates and enables growth in the generic opioid analgesic and anti-addiction markets, as well as supporting the growing demands of existing customers. 

This expansion is the first of two investments, and the second is currently undergoing commissioning. Once completed, these expansions will represent $17 million of funding.